商务合作
动脉网APP
可切换为仅中文
BASEL, Switzerland, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG ('Windward') (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced the closing of its initial public offering of 11,838,234 common shares, which includes the full exercise of the underwriters' option to purchase an additional 1,544,117 common shares, at a public offering price of $17.00 per share.
瑞士巴塞尔,2026年11月16日(环球电讯社)——Windward Bio Group AG(“Windward”)(纳斯达克股票代码:WWB),一家致力于为患有严重呼吸系统疾病和皮肤病的患者开发超长效抗体药物的临床阶段生物技术公司,今日宣布完成其首次公开募股,共发行11,838,234股普通股,其中包括承销商全额行使额外购买1,544,117股普通股的期权,公开发行价格为每股17.00美元。
Windward's common shares began trading on the Nasdaq Global Select Market under the ticker symbol 'WWB' on November 13, 2026. The gross proceeds to Windward from the initial public offering and the concurrent private placement (see below) were approximately $251.2 million. All of the common shares were offered by Windward..
Windward的普通股于2026年11月13日开始在纳斯达克全球精选市场交易,股票代码为“WWB”。Windward从首次公开发行及同步进行的私募配售(见下文)中获得的总收益约为2.512亿美元。所有普通股均由Windward发行。
In addition to the common shares sold in the initial public offering, Windward announced the closing of the concurrent sale of 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares, in each case at the initial public offering price per common share, in a private placement to Sanofi Foreign Participations B.V.
除在首次公开发行中出售的普通股外,Windward 宣布已完成向 Sanofi Foreign Participations B.V. 进行的私募配售,同步出售 1,532,691 股普通股以及可购买 1,408,485 股普通股的预付认股权证,每股普通股及每份预付认股权证的行权价格均为首发价。
for an aggregate purchase price of $50.0 million. The sale of the common shares and the pre-funded warrants was not registered under the Securities Act of 1933, as amended (the “Securities Act”)..
总购买价格为5,000万美元。本次普通股及预付权证的出售未根据经修订的《1933年证券法》(以下简称“《证券法》”)进行注册。
Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank acted as joint book-running managers for the offering.
杰富瑞、TD Cowen、Piper Sandler 和瑞银投资银行担任此次发行的联合账簿管理人。
The initial public offering was made only by means of a prospectus. Copies of the final prospectus related to the initial public offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at 877-821-7388, or by email at prospectus_department@jefferies.com; TD Securities (USA) LLC, Attn: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or by email at prospectus@psc.com or UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, New York 10010, by email at ol-prospectus-request@ubs.com..
首次公开发行仅通过招股说明书进行。与首次公开发行相关的最终招股说明书副本可从以下机构获取:Jefferies LLC,收件人:股票承销团招股说明书部门,地址:520 Madison Avenue, New York, New York 10022,电话:877-821-7388,电子邮件:prospectus_department@jefferies.com;TD Securities (USA) LLC,收件人:转交 Broadridge Financial Solutions,地址:1155 Long Island Avenue, Edgewood, NY 11717,电子邮件:TDManualrequest@broadridge.com;Piper Sandler & Co.,收件人:招股说明书部门,地址:350 North 5th Street, Suite 1000, Minneapolis, MN 55401,电话:(800) 747-3924,电子邮件:prospectus@psc.com;或 UBS Securities LLC,收件人:招股说明书部门,地址:11 Madison Avenue, New York, New York 10010,电子邮件:ol-prospectus-request@ubs.com。
A registration statement relating to the shares sold in the initial public offering was declared effective by the Securities and Exchange Commission (the 'SEC') on November 12, 2026. Copies of the registration statement can be accessed by visiting the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..
与首次公开发行中出售的股份相关的注册声明已于2026年11月12日获美国证券交易委员会(简称“SEC”)宣布生效。注册声明的副本可通过访问SEC网站www.sec.gov获取。本新闻稿不构成出售要约或购买这些证券的要约邀请,在任何州或司法管辖区,在根据该州或司法管辖区的证券法进行注册或资格认定之前,任何此类要约、邀请或销售均属违法的情况下,不得在这些州或司法管辖区销售这些证券。
About Windward Bio Group AG
关于 Windward Bio Group AG
Windward (Nasdaq: WWB) is a global, clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Its lead product candidate, WIN378, is a fully human monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and is being evaluated in the POLARIS-1 Phase 2/3 study in severe uncontrolled asthma and the SIRIUS Phase 2 study in COPD.
Windward(纳斯达克股票代码:WWB)是一家全球性的临床阶段生物技术公司,致力于为患有严重呼吸系统疾病和皮肤病(包括哮喘、慢性阻塞性肺病(COPD)和特应性皮炎)的患者开发超长效抗体药物。其核心候选产品WIN378是一种全人源单克隆抗体,旨在抑制胸腺基质淋巴细胞生成素(TSLP),目前正在针对严重未控制性哮喘的POLARIS-1 II/III期临床试验以及针对慢性阻塞性肺病的SIRIUS II期临床试验中进行评估。
Windward’s second product candidate, WIN027, is an ultra-long-acting bispecific antibody targeting TSLP and interleukin-13 (IL-13) and is currently in a Phase 1 healthy volunteer study..
Windward的第二款候选产品WIN027是一种靶向胸腺基质淋巴细胞生成素(TSLP)和白介素-13(IL-13)的超长效双特异性抗体,目前正处于针对健康志愿者的I期临床试验阶段。
For media and investor inquiries:
媒体及投资者垂询:
Noel Kurdi
诺埃尔·库尔迪
SVP, Investor Relations and Communications
投资者关系与沟通高级副总裁
investors@windwardbio.com
investors@windwardbio.com